These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3192059)

  • 1. [Clinical recovery from multiple myeloma. A report on 3 cases].
    Golenkov AK; Zlatkina AR; Grishchenko AB; Nazarova IN
    Gematol Transfuziol; 1988 Aug; 33(8):51-3. PubMed ID: 3192059
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination chemotherapy versus melphalan and prednisone in multiple myeloma.
    Gruber A; Osby E
    Chemioterapia; 1987 Jun; 6(2 Suppl):725-6. PubMed ID: 3509531
    [No Abstract]   [Full Text] [Related]  

  • 3. Researchers debate best use of stem cell transplants in patients with multiple myeloma.
    Rowan K
    J Natl Cancer Inst; 2009 Dec; 101(23):1608-11. PubMed ID: 19910555
    [No Abstract]   [Full Text] [Related]  

  • 4. [Interferon: a new weapon in the therapeutic strategy of multiple myeloma].
    Avvisati G; Petrucci MT; Mandelli F
    Haematologica; 1990; 75 Suppl 4():68-71. PubMed ID: 1705913
    [No Abstract]   [Full Text] [Related]  

  • 5. Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study.
    Grammatico S; Bringhen S; Vozella F; Siniscalchi A; Boccadoro M; Petrucci MT
    Leuk Lymphoma; 2017 Nov; 58(11):2738-2740. PubMed ID: 28402163
    [No Abstract]   [Full Text] [Related]  

  • 6. Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy.
    van Hoeven KH; Reed LJ; Factor SM
    Cancer; 1990 Oct; 66(7):1472-4. PubMed ID: 2207998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
    Steinke B; Busch FW; Becherer C; Ostendorf P; Waller HD
    Cancer Chemother Pharmacol; 1985; 14(3):279-81. PubMed ID: 3838922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The polychemotherapy of patients with multiple myeloma].
    Abdulkadyrov KM; Bessmel'tsev SS
    Vopr Onkol; 1992; 38(3):345-51. PubMed ID: 1300725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy of multiple myeloma].
    Golenkov AK
    Sov Med; 1991; (3):43-6. PubMed ID: 1882290
    [No Abstract]   [Full Text] [Related]  

  • 10. VBAMDex chemotherapy in advanced multiple myeloma.
    Peest D; Schmoll HJ; Schedel I; Glück S; Schumacher K; Deicher H
    Eur J Haematol; 1988 Mar; 40(3):245-9. PubMed ID: 3356240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 12. Tandem transplants in the treatment of multiple myeloma. Pro.
    Fassas AB; Tricot G
    Clin Adv Hematol Oncol; 2004 May; 2(5):303-4. PubMed ID: 17682284
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical importance of studying the proliferative activity of plasma cells in multiple myeloma].
    Tsykalov VA; Kasatkina VV; Kotel'nikov VM; Zhuravlev VS; Mokeeva RA
    Gematol Transfuziol; 1988 Jul; 33(7):36-40. PubMed ID: 3181725
    [No Abstract]   [Full Text] [Related]  

  • 14. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
    de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
    Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
    [No Abstract]   [Full Text] [Related]  

  • 15. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
    Kabir AL; Rahman MJ; Begum M; Dipta TF; Baqui MN; Aziz A; Rahman F; Debnath RC; Habib MA
    Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
    Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
    Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
    [No Abstract]   [Full Text] [Related]  

  • 17. [Combination chemotherapy in Alkeran-resistant myelomatosis].
    Kjølseth I; Wisløff F; Godal HC
    Tidsskr Nor Laegeforen; 1984 May; 104(13):873-4. PubMed ID: 6463973
    [No Abstract]   [Full Text] [Related]  

  • 18. Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma.
    Offidani M; Corvatta L; Liberati AM; Pulini S; Ballanti S; Bringhen S
    Leuk Lymphoma; 2018 May; 59(5):1271-1273. PubMed ID: 28891359
    [No Abstract]   [Full Text] [Related]  

  • 19. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
    Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
    Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.